East Indian sandalwood oil(East Indian sandalwood oil) - 药物靶点：PDE4_专利_临床

概要

基本信息

药物类型

小分子化药

别名

SAN-007、SAN-021、VIR-003

+ [1]

靶点

PDE4

作用方式

抑制剂

作用机制

PDE4抑制剂(磷酸二酯酶4抑制剂)

治疗领域

免疫系统疾病感染遗传病与畸形+ [2]

在研适应症-

非在研适应症

尖锐湿疣特应性皮炎湿疹+ [1]

原研机构

Santalis Pharmaceuticals, Inc.

在研机构-

非在研机构

Santalis Pharmaceuticals, Inc.

ViroXis Corp.

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 East Indian sandalwood oil 相关的临床试验

NCT03000595

/ Withdrawn临床2期

A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis

This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28 days to patients from 3 months to 65 years of age, with atopic dermatitis.

开始日期2018-06-01

申办/合作机构

Santalis Pharmaceuticals, Inc.

[+1]

NCT03158974

/ Terminated临床2期

A Phase 2, Open-label, Safety, Tolerability, and Efficacy Trial of a Botanical Drug at One Dose Level for the Treatment of External Condylomata Acuminata (Genital Warts) in Adult Immunocompetent Subjects

This trial will be a phase 2, open-label, study to evaluate the safety, tolerability, and efficacy of VIR007 when administered topically for up to 60 days to adults between the ages of 18 to 65 years with a clinical diagnosis of external condylomata acuminata.

开始日期2017-08-01

申办/合作机构

ViroXis Corp.

NCT02871479

/ Completed临床2期

A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis

This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28 days to patients at least 18 years of age, with atopic dermatitis.

开始日期2017-04-21

申办/合作机构

Santalis Pharmaceuticals, Inc.

[+4]

100 项与 East Indian sandalwood oil 相关的临床结果

登录后查看更多信息

100 项与 East Indian sandalwood oil 相关的转化医学

登录后查看更多信息

100 项与 East Indian sandalwood oil 相关的专利（医药）

登录后查看更多信息

100 项与 East Indian sandalwood oil 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
尖锐湿疣	临床2期	美国	ViroXis Corp.	2017-08-01
银屑病	临床2期	美国	Santalis Pharmaceuticals, Inc.	2017-05-17
特应性皮炎	临床2期	美国	Santalis Pharmaceuticals, Inc.	2017-04-21
湿疹	临床2期	美国	Santalis Pharmaceuticals, Inc.	2017-04-21

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02871479 (CTgov)	临床2期	湿疹 \| 特应性皮炎	71	SAN007 (SAN007 5% Cream)	顧鏇選糧鬱膚衊網淵糧 = 願窪顧鑰壓鑰繭壓顧築築遞製窪廠積遞遞衊遞 (醖築膚繭鬱積鬱築積鏇, 糧齋製願醖餘網網蓋範 ~ 顧鹽鬱網簾鏇衊膚餘製) 更多	-	2019-05-29
				Placebo (Placebo Cream)	顧鏇選糧鬱膚衊網淵糧 = 蓋膚鑰鹽遞糧壓觸襯糧築遞製窪廠積遞遞衊遞 (醖築膚繭鬱積鬱築積鏇, 壓繭築憲繭鏇鹽衊獵餘 ~ 選餘觸醖鑰鏇窪繭願製) 更多